8 results found.

Fabry Disease Clinical Trial

Baylor Research Institute - Recruiting 18 years to 64 years.
- Androgenetic Alopecia in Fabry Disease.

Fabry Disease Clinical Trial using agalsidase alfa

Shire Development LLC - Recruiting N/A or older.
- A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagalr (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease.
agalsidase alfa

Fabry Disease Clinical Trial using migalastat HCl

Amicus Therapeutics - Recruiting 18 years to 74 years.
- Physician Initiated Request for Treatment Use of Migalastat Hydrochloride (GR181413A/AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (MGM116188).
migalastat HCl

Fabry Disease Clinical Trial using Iohexol

Sanofi - Recruiting 5 years to 25 years.
- A Cross-sectional Study of Renal Function in Treatment-na‹ve, Young Male Patients With Fabry Disease.

Fabry Disease Clinical Trial using agalsidase beta

Sanofi - Recruiting N/A or older.
- A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants.
agalsidase beta

Fabry Disease Clinical Trial using migalastat HCl 150mg

Amicus Therapeutics - Recruiting 16 years or older.
- An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease.
migalastat HCl 150mg

Fabry Disease, or Cerebrovascular Accident Clinical Trial using No intervention

University of Rostock - Recruiting 18 years to 55 years.
- Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study.
No intervention

Fabry Disease Clinical Trial using recombinant alpha-galactosidase A

Assistance Publique - H“pitaux de Paris - Recruiting 15 years or older.
- A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease.
recombinant alpha-galactosidase A